KeyBanc analyst Scott Schoenhaus raised the firm’s price target on R1 RCM to $20 from $15 and keeps an Overweight rating on the shares. The firm thinks "beat and raise" quarters are likely for this year and beyond.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RCM:
- R1 RCM downgraded to Hold from Buy at Truist
- R1 RCM to Release Fourth Quarter 2022 Results on February 16
- R1 RCM Announces Leadership Appointments; Reaffirms 2022 Guidance and Announces 2023 Outlook
- R1 RCM initiated with a Buy at Canaccord
- R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference
